Abstract

BackgroundChronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that arises from the acquisition of constitutively active BCR‐ABL tyrosine kinase in hematopoietic stem cells. The persistence of bone marrow leukemia stem cells (LSCs) is the main cause of TKI resistance and CML relapse. Therefore, finding a key target or pathway to selectively target LSCs is of great significance for the thorough treatment of CML.MethodsIn this study, we aimed to identify key microRNAs, microRNA targets and pathways for the treatment of CML LSCs by integrating analyses of three microarray data profiles. We identified 51 differentially expressed microRNAs through integrated analysis of GSE90773 and performed functional gene predictions for microRNAs. Then, GSE11889 and GSE11675 were integrated to obtain differentially expressed genes (DEGs), and the overlapping DEGs were used as models to identify predictive functional genes. Finally, we identified 116 predictive functional genes. Clustering and significant enrichment analysis of 116 genes was based on function and signaling pathways. Subsequently, a protein interaction network was constructed, and module analysis and topology analysis were performed on the network.ResultsA total of 11 key candidate targets and 33 corresponding microRNAs were identified. The key pathways were mainly concentrated on the PI3K/AKT, Ras, JAK/STAT, FoxO and Notch signaling pathways. We also found that LSCs negatively regulated endogenous and exogenous apoptotic pathways to escape from apoptosis.ConclusionWe identified key candidate targets and pathways for CML LSCs through bioinformatics methods, which improves our understanding of the molecular mechanisms of CML LSCs. These candidate genes and pathways may be therapeutic targets for CML LSCs.

Highlights

  • Chronic myelogenous leukemia (CML) is a stem cell cancer that develops as a result of the t(9;22) translocation in hematopoietic stem cells (HSCs) (Nowell & Hungerford, 1961; Rowley, 1973)

  • This translocation results in constitutive expression of the fusion tyrosine kinase BCR‐ ABL1(Heisterkamp et al, 1983) and transformation of HSCs into leukemic stem cells (LSCs)

  • Recent evidence suggests that in approximately 50%–60% of lifelong tyrosine kinase inhibitors (TKIs) patients, leukemia stem cells (LSCs) persist; this is a primary cause of TKI resistance (Chomel et al, 2011; Chu et al, 2011; Holyoake, Jiang, Eaves, & Eaves, 1999), and if TKI treatment is discontinued, it can serve as a reservoir for disease recurrence (Chen & Kang, 2015; Copland et al, 2006; Jorgensen, Allan, Jordanides, Mountford, & Holyoake, 2007)

Read more

Summary

Introduction

Chronic myelogenous leukemia (CML) is a stem cell cancer that develops as a result of the t(9;22) translocation in hematopoietic stem cells (HSCs) (Nowell & Hungerford, 1961; Rowley, 1973) This translocation results in constitutive expression of the fusion tyrosine kinase BCR‐ ABL1(Heisterkamp et al, 1983) and transformation of HSCs into leukemic stem cells (LSCs). To improve the cure rate of CML, there is a significant need to develop new therapeutic methods that target LSCs. MicroRNAs are small noncoding RNAs that participate in the posttranscriptional regulation of gene expression. Researchers integrated four cohort profile datasets to elucidate the potential key candidate genes and pathways in colorectal cancer (Guo, Bao, Ma, & Yang, 2017). Methods: In this study, we aimed to identify key microRNAs, microRNA targets and pathways for the treatment of CML LSCs by integrating analyses of three microarray data profiles. These candidate genes and pathways may be therapeutic targets for CML LSCs

Objectives
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call